| Document |
Document Title |
|
WO/2002/085838A1 |
The present invention relaters to copper-catalyzed carbon-heteroatom and carbon-carbon bond-forming methods. In certain embodiments, the present invention relates to copper-catalyzed methods of forming a carbon-nitrogen bond between the ...
|
|
WO/2002/085829A1 |
A process for production of dimers of aromatic monohydroxyl compounds, characterized by conducting the oxidative coupling of an aromatic compound represented by the general formula [I]: Ar-OH [I] (wherein Ar is an optionally substituted ...
|
|
WO/2002/085836A1 |
A binaphtol derivative represented by the following general formula [1]: [1] and a salt of the derivative.
|
|
WO2001058855A9 |
Substituted phenylalanines are provided comprising an hydantoin, urea or 2-hydroxyl, 2-methylpropionyl group, dimers thereof and alkyl, polyfluoroamido and haloarylamino derivatives thereof, as well as radiolabeled derivatives thereof. T...
|
|
WO/2002/083627A2 |
The invention relates to the novel biphenyl derivatives of the general formula (I), wherein R1, R1', R1'', R2 and n are defined as in claim 1. The invention also relates to the stereoisomers and the physiologically acceptable salts or so...
|
|
WO/2002/078686A1 |
The invention relates to the use of retinyl carbonates of formula (I), wherein R represents an optionally substituted C¿1?-C¿12? alkyl, C¿6?-C¿12? aryl, C¿7?-C¿13? aralkyl or a group of formula (II), for the cosmetic treatment of t...
|
|
WO/2002/076402A2 |
The invention provides conjugates of fatty amines and pharmaceutical agents useful in treating cancers, viruses, psychiatric disorders. Compositions, pharmaceutical preparations, and methods of preparations of the fatty amine-pharmaceuti...
|
|
WO/2002/076930A2 |
Substituted diarylureas, pharmaceutical compositions containing them, and their use for stimulating Fas-mediated apoptosis. The compounds, as single stereoisomers or mixtures of stereoisomers, their pharmaceutically acceptable salts, and...
|
|
WO/2002/076929A1 |
In one embodiment, this invention provides a novel class of compounds as antagonists of the MCH receptor, methods of preparing such compounds, pharmaceutical compositions containing one or more of the compounds, methods of preparing phar...
|
|
WO/2002/072534A2 |
The invention relates novel butane acid derivatives containing a cyanide group, pharmaceutical compositions containing butane acid derivatives and the use of said butane acid derivatives in the production of pharmaceutical compositions f...
|
|
WO/2002/072536A1 |
The invention relates to novel compounds having Vanilloid Receptor (VR1) antagonist activity, processes for their preparation, to compositions containing them and to their use in the treatment of various disorders.
|
|
WO/2002/072083A1 |
The nonenzymatic glycation and crosslinking of proteins is a part of the aging process with the glycation endproducts and crosslinking of long-lived proteins increasing with age. This process is increased at elevated concentrations of re...
|
|
WO/2002/070493A1 |
The invention relates to a bisaryl derivative of the formula I, wherein (R, R) is selected from (H, H), O, (H, CH¿3?), (H, OH) and (H, CN); Ar is substituted phenyl; and A is a group of following formula II, III, IV or V: The compounds ...
|
|
WO/2002/070471A1 |
Compounds of the formula (I) in which R?1¿ is CN, or C(=NH)-NH¿2?, CON(R?3¿)¿2? or [C(R?4¿)¿2?]¿n?N(R?3¿)¿2?, each of which is unsubstituted or monosubstituted by C(=O)R?3¿, COOR?3¿, or?3¿ or by a conventional amino-protectin...
|
|
WO/2002/068380A1 |
The present invention provides novel compounds that affect certain excitatory amino acid receptors, and are useful in the treatment of neurological disorders and psychiatric disorders.
|
|
WO2000066104A9 |
ACE-2 inhibiting compounds are disclosed. Methods of using the compounds and pharmaceutical compositions containing the compounds are also claimed.
|
|
WO2000067746A9 |
A method for the inhibition of the binding of alpha 4 beta 1 integrin to its receptors, for example VCAM-1 (vascular cell adhesion molecule-1) and fibronectin; compounds that inhibit this binding; pharmaceutically active compositions com...
|
|
WO/2002/064139A1 |
This invention relates to the use of the combined action of a compound with neurotrophic activity and a compound enhancing the dopamine activity for the treatment of Parkinson's disease.
|
|
WO/2002/064128A1 |
The invention relates to the use of a compound that modulates the association of caspase-9 to Apaf-1 for the treatment of diseases characterized by excessive or insufficient cell death.
|
|
WO/2002/064549A1 |
PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certan plasma lipid levels, including high density liporprotein-cholesterol and to lower certain other plasma lipid lev...
|
|
WO/2002/064130A1 |
PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipo-protein-cholesterol and to lower certain plasma lipid levels, ...
|
|
WO/2002/062763A2 |
This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
|
|
WO/2002/062762A2 |
Compounds of formula (I) are useful in treating diseases prevented by or ameliorated with potassium channel openers. Also disclosed are potassium channel opening compositions and a method of opening potassium channels in a mammal.
|
|
WO/2002/059077A1 |
It is intended to provide drugs which have cholesteryl ester transfer protein inhibitory effect and are useful as blood lipid lowering agent, etc. Namely, compounds represented by the following general formula (I), salts thereof, and med...
|
|
WO/2002/059080A2 |
The present invention relates to novel, non-peptidic small organic compounds having an affinity for cyclophilin (CyP)-type immunophilin proteins, and to pharmaceutical compositions comprising one or more of the said compounds. The invent...
|
|
WO/2002/059102A2 |
The invention concerns novel products of formula (I) wherein: Y represents oxygen or sulphur; Z represents C=CH2, CH-CH3 or CH2; R1 represents hydrogen, morpholinyl or the radical (II) wherein the two nitrogen atoms are linear or form a ...
|
|
WO/2002/059081A2 |
Urea and amide derivatives inhibit cell function of the chemokine receptor CCR-3. These compounds offer an effective means for treating a range of diseases thought to be mediated by the CCR-3 receptor. A variety of useful area and amide ...
|
|
WO/2002/057242A2 |
Novel antagonists of &agr 4β1 integrin and/or &agr 4β7 integrin of the general Formula (I): wherein R1, R2, R5, L1, L2, Rb, W and Z are as defined in any one of claims 1 to 13, A represents -CH- or a nitrogen atom, and p is from 0 to 4.
|
|
WO/2002/057233A1 |
The present invention related to compounds of the formula (I) or a pharmaceutically acceptable addition salt and/or hydrate thereof, or where applicable, a geometric or optical isomer or racemic mixture thereof; which are useful for the ...
|
|
WO2001040188A9 |
The present invention is directed to curcumin analogs (I), wherein Y is OH, halogen, or CF3; Z is H, OH, OR1, halogen, or CF3; X1 and X2 are independently C or N; and A is as defined in the application; exhibiting anti-tumor and anti-ang...
|
|
WO/2002/053523A1 |
A tropolone derivative represented by the formula (I) which has retinoid activity and is useful as an active ingredient for medicines [R?1¿ to R?4¿ each represents hydrogen, alkyl, or alkoxy; ring Ar represents an aryl ring or heteroar...
|
|
WO2000064911A9 |
The present invention relates to novel compounds and formulations thereof which compounds are ligands, e.g., agonists or antagonists, for a metabotropic glutamate receptor or a NAALADase enzyme or both. The present invention also relates...
|
|
WO/2002/053534A1 |
Compounds represented by the general formula (I) or salts thereof, and medicines containing the same: (I) [wherein W is W?A¿-A?1¿-W?B¿- (wherein W?A¿ is optionally substituted aryl or the like; A?1¿ is -NR?1¿-, a single bond, -C(O)...
|
|
WO2000073263A9 |
A composition is provided comprising a novel cationic lipid compound having hydrophobic tails and two quaternary ammonium headgroups bridged by a linker. The composition is useful as a cytofectin for facilitating delivery and transfectio...
|
|
WO/2002/051810A2 |
The invention relates to novel compounds, to the use thereof as the ligands of integrin receptors, especially for the use as the ligands of the $g(a)¿v?$g(b)¿3? integrin receptor, as well as to pharmaceutical preparations that contain ...
|
|
WO/2002/051799A1 |
Biphenyl derivatives represented by the general formula (1) or salts thereof; and ACAT inhibitors or medicines containing the same as the active ingredient: (1) [wherein R?1¿ is C¿5-7? alkyl; R?2¿ is optionally substituted aromatic hy...
|
|
WO/2002/050052A1 |
The invention relates to compounds of formula (I), wherein R¿1? is aryl unsubstituted or mono- to penta-substituted by R¿7? or is heteroaryl unsubstituted or mono- to tetra-substituted by R¿7? it being possible for the substituents in...
|
|
WO/2002/050019A2 |
The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma, multiple sclerosis, atherosclerosis, and rheumatoid arthritis.
|
|
WO/2002/048099A1 |
The invention relates to compounds of formula (I), wherein the variables have the following meanings: D means a phenyl or a pyridyl which is unsubstituted or is mono- or polysubstituted by Hal, A, OR?2¿, N(R?2¿)¿2?, NO¿2?, CN, COOR2 ...
|
|
WO/2002/046141A2 |
The present invention provides compounds that elevate cellular expression of the ABCA-1 gene, promoting cholesterol efflux from cells and increasing HDL levels in the plasma of a mammal, in particular humans. The compounds are useful for...
|
|
WO1999059957A9 |
Compounds of formula (I) wherein the groups are as defined in the description are disclosed. The compounds of formula (I) are endowed with reversible inhibiting activity of carnitine palmitoyl-transferase and are useful in the preparatio...
|
|
WO/2002/046172A2 |
The present invention provides compounds that elevate cellular expression of the ABCA-1 gene, promoting cholesterol efflux from cells and increasing HDL levels in the plasma of a mammal, in particular humans. The compounds are useful for...
|
|
WO/2002/046181A2 |
The present invention provides compounds that elevate cellular expression of the ABCA-1 gene, promoting cholesterol efflux from cells and increasing HDL levels in the plasma of a mammal, in particular humans. The compounds are useful for...
|
|
WO/2002/046146A1 |
Novel substituted carboxylic acid derivatives which bind to human peroxisome proliferator-activated receptor a (PPARa) as a ligand thereof and activate the same to thereby exert a lipid-lowering effect, an arteriosclerosis-preventing eff...
|
|
WO/2002/044126A2 |
The present invention relates to novel, non-peptidic small organic compounds having an affinity for cyclophilin (CyP)-type immunophilin proteins. In the compounds of this invention, at least two carbo-or heterocyclic groups are attached ...
|
|
WO2001021160B1 |
The present invention relates to the use of carboxamide compounds as selective inhibitors of pathogens, particularly viruses and, more particularly, herpesviridae. Surprisingly, these compounds show reduced side effects in comparison wit...
|
|
WO/2002/042248A2 |
The present invention relates to naphthalene derivatives of formula (I), wherein X is S, S(O), S(O)¿2?, S(O)¿2?NH, P(O)OCH¿3?, P(O)OH, NH, N(CH¿3?), NHC(O)NH, C(O), C(O)O, NHC(O), CH(OH), CH=N, CH=CH, CH¿2?NH, C(=NH); R?1¿ is aryl ...
|
|
WO/2002/042257A1 |
The invention relates to substituted cyclohexane derivates of formula (I), a method for the production thereof and the use thereof in medicaments, particularly for preventing and/or treating cardiovascular diseases, diseases of the uroge...
|
|
WO/2002/040446A1 |
A novel class of compounds of the general formula (I): wherein Z is arylene or a divalent radical derived from a 5 or 6 membered heteroaromatic ring E is which act to antagonize the action of the glucagon hormone on the glucagon receptor...
|
|
WO/2002/040444A1 |
Novel compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any di...
|
